AGA Nanotech Awarded Best Pitch at SBC Catalyser Programme 2024

AGA Nanotech is proud to announce that we have been awarded Best Pitch at the prestigious SBC Catalyser Programme 2024, delivered by Stevenage Bioscience Catalyst (SBC) and Triple Chasm. Our innovative non-antibiotic antimicrobial technology, market positioning, and commercialisation plans were critically assessed thrugh the SBC Triple Chasm Programme. The SBC Catalyser Programme evaluates pioneering huan health companies through 9 meso-economic vectors. AGA Nanotech was selected as one of only eight companies to participate in the 2024 Triple Chasm programme, which involved an in-depth assessment of our technology, market strategy, and commercialisation potential. The programme is led by experts Dr. Uday Phadke and Sam Dods, who bring a wealth of knowledge and experience in accelerating biotech innovations.

Our CEO, Harsha Siani, delivered a compelling pitch to a distinguished audience of leaders from pharmaceutical and medical device companies, investors, and entrepreneurs. The pitch highlighted the unique aspects of our Battlestar technology, which offers broad-spectrum efficacy, low cytotoxicity, and does not contribute to antimicrobial resistance. The judging panel for the pitch included notable industry figures such as Dr. Sally Ann Forsyth OBE (CEO of SBC), Graham Rivers (VP at GSK), and Oliver Hardick (previous founder of Puridify, an SBC-company that was sold to GE Healthcare, now EIR at M Ventures). Their recognition of AGA Nanotech’s potential is a significant endorsement of our vision and strategy.